AnteoTech Ltd (ADO) AI Stock Analysis

• Market Cap: AU$51.82M
• Dividend Yield: N/A
• Average Volume (3M): 1.47M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: 110.44%
• EPS Growth: 35.90%
• Country: AU
• Employees: 24
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 2,727,438,700
• 10 Day Avg. Volume: 1,501,441
• 30 Day Avg. Volume: 1,471,917
• PEG Ratio: 0.14
• Price to Book (P/B): 10.79
• Price to Sales (P/S): 35.07
• P/FCF Ratio: -5.62
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: AU$0.02 ▼(-10.00% Downside)

The score is mainly constrained by weak financial performance, driven by revenue volatility, persistent losses, and negative operating/free cash flows. Technicals add risk due to extremely overbought RSI, while valuation is also pressured by a negative P/E and no dividend yield data.

Positive Factors

Proprietary technology

AnteoTech's proprietary surface chemistry and nanotechnology form a durable competitive asset, enabling differentiated performance in diagnostics and biosensors. Such platform IP supports multiple product applications, raises entry barriers, and underpins long-term licensing and product partnerships.

Diversified revenue streams

Multiple monetization paths—licensing, direct product sales, R&D partnerships and grants—reduce reliance on a single sales channel. This structural diversity can stabilize cash flows over time, enable scalable royalty income, and support commercialization even if one channel underperforms.

Manageable leverage

A moderate debt-to-equity ratio (~0.62) provides financial flexibility versus highly levered peers, allowing the company to fund R&D and commercial initiatives without excessive interest burden. This balance supports multi-month runway and strategic investment capacity if cash generation improves.

Negative Factors

Revenue volatility

Sharp, large negative revenue swings impair forecasting, partner confidence, and pricing negotiation. Structural revenue instability suggests commercialization challenges and dependence on sporadic deals, forcing recurrent financing and undermining the company's ability to scale sustainably over quarters.

Persistent unprofitability

Sustained negative net, EBIT and EBITDA margins indicate the company cannot yet convert gross profitability into operating profit. Continued losses erode equity and limit reinvestment into product development and commercialization, risking dilution or financial distress absent margin recovery.

Weak cash generation

Negative operating and free cash flows reflect structural cash burn, constraining R&D and go-to-market investment. Reliance on external funding increases dilution and execution risk; even with a modest FCF improvement, persistent cash deficits threaten runway over the medium term.

AnteoTech Ltd Business Overview & Revenue Model

Company Description

AnteoTech Limited, a surface chemistry company, develops, commercializes, manufactures, and distributes products for the life sciences, diagnostics, energy, and medical device markets primarily in Australia. Its products include AnteoBind ready-to-use kits to streamline and enhance the conjugation process; AnteoX, an additive that reinforces battery binders helping maximize performance of silicon containing anodes; EuGeni, a COVID-19 antigen rapid test; and AnteoRelease and AnteoCoat. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited is headquartered in Eight Mile Plains, Australia.

How the Company Makes Money

AnteoTech generates revenue primarily through the commercialization of its proprietary technology and products in the diagnostics and medical device markets. Key revenue streams include licensing agreements with other companies that utilize AnteoTech's technology in their products, direct sales of its diagnostic solutions, and research and development partnerships with healthcare organizations and research institutions. Additionally, AnteoTech may benefit from grants and funding aimed at supporting biotechnological innovations, further contributing to its earnings.

AnteoTech Ltd Financial Statement Overview

Summary

AnteoTech Ltd faces significant financial challenges across all verticals. The income statement reflects ongoing losses and revenue volatility, while the balance sheet shows moderate leverage but poor returns on equity. Cash flow issues persist, with negative operating and free cash flows. The company needs to address profitability and cash flow generation to improve its financial health.

Income Statement

AnteoTech Ltd has experienced significant revenue volatility, with a notable decline in revenue growth rate of -277.78% in the most recent period. The company consistently reports negative net profit margins, with the latest at -6.98%, indicating ongoing profitability challenges. The EBIT and EBITDA margins are also negative, reflecting operational inefficiencies. Despite a high gross profit margin, the overall income statement performance is weak due to persistent losses.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.62, suggesting manageable leverage. However, the return on equity is negative at -2.15%, indicating that the company is not generating returns on shareholder investments. The equity ratio is not explicitly calculated, but the declining stockholders' equity over time suggests weakening financial stability.

Cash Flow

AnteoTech Ltd's cash flow statement reveals negative operating and free cash flows, with a slight improvement in free cash flow growth rate at -12.83%. The operating cash flow to net income ratio is negative, highlighting cash flow challenges. The free cash flow to net income ratio is slightly above 1, indicating that free cash flow is somewhat aligned with net income, but overall cash flow performance remains weak.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.06M	968.88K	460.40K	365.72K	760.88K	898.07K
Gross Profit	2.06M	968.88K	460.40K	365.72K	760.88K	898.07K
EBITDA	-4.19M	-7.96M	-11.57M	-12.35M	-12.07M	-7.18M
Net Income	-4.48M	-6.76M	-8.88M	-12.65M	-10.72M	-6.22M
Balance Sheet
Total Assets	6.45M	6.45M	9.38M	5.36M	15.26M	23.68M
Cash, Cash Equivalents and Short-Term Investments	2.34M	2.34M	5.03M	2.72M	10.10M	21.39M
Total Debt	1.96M	1.96M	2.31M	1.31M	1.03M	1.28M
Total Liabilities	3.30M	3.30M	4.08M	2.99M	2.91M	2.56M
Stockholders Equity	3.15M	3.15M	5.31M	2.38M	12.36M	21.11M
Cash Flow
Free Cash Flow	-3.72M	-6.05M	-7.58M	-8.77M	-11.77M	-4.76M
Operating Cash Flow	-3.54M	-5.83M	-6.52M	-8.08M	-8.65M	-4.55M
Investing Cash Flow	-174.87K	-174.87K	-1.06M	-690.83K	-3.12M	-213.07K
Financing Cash Flow	3.32M	3.32M	9.89M	1.39M	482.29K	22.94M

AnteoTech Ltd Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:ADO, the sentiment is Positive. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 92.14 is Negative, neither overbought nor oversold. The STOCH value of 58.89 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:ADO.

AnteoTech Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CYP	52 Neutral	AU$92.61M	-8.30	-138.54%	―	―	16.61%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPL	51 Neutral	AU$159.57M	-14.79	-41.51%	―	-40.74%	-21.21%
PIQ	51 Neutral	AU$108.91M	-11.01	-71.87%	―	7.65%	-19.13%
PTX	50 Neutral	AU$91.48M	-9.23	-49.72%	―	―	10.78%
AVE	44 Neutral	AU$33.06M	-9.09	-143.71%	―	306.88%	―
ADO	38 Underperform	AU$51.82M	-8.00	-159.86%	―	110.44%	35.90%

AnteoTech Ltd Corporate Events

AnteoTech CFO and Company Secretary Andrew Cook Resigns

AnteoTech Ltd has announced the resignation of Andrew Cook from his dual roles as Chief Financial Officer and Company Secretary, as he departs to pursue other business interests. The board has commenced a process to identify his successor and has committed to an orderly transition under his existing employment terms, with further updates on interim and permanent arrangements to follow, signalling a period of financial and governance reshaping that stakeholders will watch closely given his central role in the company’s corporate and reporting functions.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Wins Serum Institute Order as Life Sciences Pipeline Accelerates

AnteoTech has secured a US$185,000 AnteoBind order from the Serum Institute of India under its five-year supply agreement, with shipment set for early January 2026, while simultaneously deepening the relationship through SII’s evaluation of a new AnteoBind-activated ELISA plate prototype targeting a market that accounts for roughly 40% of the global immunoassay segment. The company reports growing momentum in its Life Sciences business, including approximately AU$70,000 in new sales to Japanese customers, a sharp increase in AnteoBind NXT evaluations across major global markets, re-engagement with large life sciences players on joint CLIA and ELISA product development, and a strategic shift from additive supplier to core-ingredient provider, supported by recent peer-reviewed publications and expanded commercial activity in India, positioning AnteoTech to tap into the sizeable and fast-growing CLIA and ELISA markets in 2026 and beyond.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Ltd Advances High Silicon Anode Performance

AnteoTech Ltd has presented an update on its business activities, specifically highlighting advancements in maximizing high silicon anode performance. This development is significant for the company as it could enhance its position in the energy storage sector, potentially leading to improved operational efficiencies and market competitiveness.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Announces Director’s Change in Securities Holdings

AnteoTech Ltd has announced a change in the interests of its director, Glenda McLoughlin, involving the acquisition of 7,500,000 unlisted options and the expiry of 5,000,000 unlisted options. This adjustment in the director’s securities holdings reflects ongoing strategic decisions within the company, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Ltd Issues 42.5 Million Unquoted Options to Boost Growth

AnteoTech Ltd has announced the issuance of 42.5 million unquoted options, exercisable at $0.0375, with expiration dates in 2028 and 2029. This strategic move could potentially enhance the company’s financial flexibility and strengthen its market position by providing additional capital for growth and development.

The most recent analyst rating on (AU:ADO) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on AnteoTech Ltd stock, see the AU:ADO Stock Forecast page.

AnteoTech Ltd Secures Strong Shareholder Support at 2025 AGM

AnteoTech Ltd announced the results of its 2025 Annual General Meeting, where all resolutions were passed by poll. Notably, less than 25% of votes were against the adoption of the 2025 remuneration report, eliminating the need to consider contingent resolution 6. This outcome reflects strong shareholder support and may positively impact AnteoTech’s governance and strategic initiatives, reinforcing its position in the advanced materials industry.

AnteoTech Ltd Reports Strategic Progress and Revenue Growth at 2025 AGM

AnteoTech Ltd’s 2025 AGM highlighted strategic advancements and operational restructuring under new leadership. The company reported significant progress in its Life Sciences division with the launch of AnteoBind NXT™ and a renewed agreement with the Serum Institute of India, resulting in a 110% revenue increase. In Advanced Battery Technologies, AnteoTech’s Ultranode™ X formulation achieved a major milestone, enhancing its competitiveness in the lithium-ion battery market. The company also expanded its customer engagement and entered a joint development agreement to strengthen its position in the global battery supply chain.

AnteoTech Achieves Milestone with Ultranode™ X Anode for EVs and eVTOLs

AnteoTech Ltd has announced a significant milestone with its Ultranode™ X anode, achieving over 1,000 charge/discharge cycles at 80% capacity retention. This development positions AnteoTech as a competitive player in the EV and eVTOL markets, offering a cost-effective and scalable anode technology. The achievement is expected to accelerate customer and partnership discussions, leveraging the use of micron-sized silicon materials that are less costly and more environmentally friendly compared to traditional composites. This advancement comes at a critical time as global supply chains face challenges, particularly with recent export restrictions from China, highlighting AnteoTech’s strategic advantage in providing trade restriction-independent solutions.

AnteoTech Scales Up Ultranode™ 70 Production for Wyon AG

AnteoTech Ltd has achieved a significant milestone by scaling up the production of its Ultranode™ 70 silicon anode for Wyon AG, a Swiss battery manufacturer. This development marks a crucial step in the commercialisation of AnteoTech’s technology, as it prepares for performance evaluations by Wyon. The successful integration of Ultranode™ 70 is expected to enhance energy capacity and battery life, potentially leading to a commercial supply agreement with Wyon, thereby strengthening AnteoTech’s position in the consumer battery market.

AnteoTech Expands Market Reach and Strengthens Operations in Q3 2025

AnteoTech Ltd has made significant strides in its operations during the quarter ending September 30, 2025, by executing a Joint Development and Sales Agreement with Black Diamond Structures and achieving a tenfold manufacturing scale-up of its Ultranode material. The company has also expanded its market presence by appointing a South Korean distributor and participating in international conferences, which has resulted in increased customer engagement and new sales leads. In the life sciences sector, AnteoTech has strengthened its collaborations and market engagement, leading to new orders and partnerships. The company has also appointed a new CEO, implemented a CRM system, and received a substantial R&D Tax Incentive, all while maintaining a strong cash position with no debt.

AnteoTech Ltd Announces Potential Spill Meeting Post-AGM

AnteoTech Ltd has announced a Notice of General Meeting concerning a potential spill meeting following its 2025 Annual General Meeting. This meeting, if necessary, is scheduled for November 26, 2025, in Brisbane. The announcement is significant as it could impact the company’s governance and strategic direction, potentially affecting stakeholders’ interests.